首页 > 市场调查报告书 > 製药

呼吸器

遗传性慢性阻塞性肺病 (COPD) 市场，按药物类别、给药途径、分销渠道、地区 - 规模、份额、前景、机会分析，2023-2030 年

市场调查报告书

商品编码

1233364

遗传性慢性阻塞性肺病 (COPD) 市场，按药物类别、给药途径、分销渠道、地区 - 规模、份额、前景、机会分析，2023-2030 年

Genetic Chronic Obstructive Pulmonary Disease Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年01月27日 | 出版商:

Coherent Market Insights | 英文 178 Pages | 商品交期: 2-3个工作天内

价格

简介目录

与 alpha-1 缺乏相关的肺气肿称为遗传性。慢性阻塞性肺病 (COPD) 涉及肺部炎症，可导致肺部气流受阻。它是一种慢性疾病，症状包括喘息、粘液分泌和呼吸困难。慢性支气管炎、肺气肿和顽固性哮喘都是 COPD 的症状，COPD 是一种肺部退行性疾病。慢性阻塞性肺病 (COPD) 最常由吸烟、空气污染、二手烟和 alpha-1 缺乏相关肺气肿（一种罕见的 COPD 形式）引起。

每年，有数百万人患有慢性阻塞性肺病，简称 COPD。肺气肿和慢性支气管炎是两种统称为慢性阻塞性肺病的疾病。在肺气肿中，肺部的气囊（称为肺泡）受损。运动时呼吸急促是肺气肿的第一个征兆。甚至在休息时也可能出现呼吸困难。慢性阻塞性肺病 (COPD) 的四个阶段从轻微到非常严重。症状包括持续咳嗽、呼吸急促和喘息。

市场动态

市场主要参与者越来越多地采用有机策略，例如产品发布和批准，预计将在预测期内推动市场增长。例如，2020 年 9 月，製药公司 GSK, Plc. 和专注于医疗保健的资产管理公司 Innoviva Inc. 宣布，美国食品药品监督管理局 (FDA) 已批准 Trelegy Ellipta（氟替卡松漂浮物/乌克溴铵/维兰特罗）。FF/UMEC/VI”）用于治疗 18 岁及以上患者的哮喘，扩大批准用于当前患有慢性阻塞性肺疾病（COPD）的患者。 Trelegy Ellipta 不适用于缓解急性支气管痉挛。此外，还有多种针对 COPD 呼吸系统疾病的前瞻性药物正在研发中，有望推动全球遗传性角化阻塞性肺病（COPD）市场的增长。

这项研究的主要特点

本报告对全球遗传性慢性阻塞性肺疾病 (COPD) 治疗市场进行了深入分析，揭示了以 2022 年为基准年的预测期 (2023-2030) 的市场规模和復合年增长率。 (CAGR%) 发布。
它还阐明了各个细分市场的潜在创收机会，并描述了该市场具有吸引力的投资建议矩阵。
它还提供了市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争战略的关键考虑因素。本文根据以下参数介绍了全球遗传性慢性阻塞性肺病 (COPD) 治疗市场主要参与者的概况：公司亮点、产品组合、主要亮点、财务业绩和战略。
本研究涵盖的主要公司 GSK Plc.、AstraZeneca Plc.、Merck (Sigma-Aldrich)、Dey Pharma、Grifols, S.A.、Teva Pharmaceutical Industries Ltd、Baxter、Boehringer Ingelheim International GmbH、Kamada Ltd、Takeda Pharmaceutical Company Limited、LFB SA、Abeona Therapeutics、Alnylam Pharmaceuticals, Inc.、Vertex Pharmaceuticals Incorporated、Kedrion S.p.A. 和 Arrowhead Pharmaceuticals, Inc.
这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
《全球遗传性慢性阻塞性肺疾病 (COPD) 治疗市场报告》面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
利益相关者可以通过用于分析全球遗传性慢性阻塞性肺疾病 (COPD) 治疗市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写

第二章市场概况

报告内容
- 市场定义和范围
执行摘要
- 市场概况：按药物类别
- 按给药途径划分的市场概况
- 市场概况：按分销渠道
- 市场概况：按地区
连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

市场动态
- 司机
- 约束因素
- 市场机会
监管情景
主要亮点
关于研发合作伙伴关係和併购
害虫分析
管道解析
流行病学

第 4 章遗传性慢性阻塞性肺疾病 (COPD) 的全球市场 - 冠状病毒 (COVID-19) 大流行的影响

总体影响
政府举措
COVID-19 对市场的影响

第 5 章按药物类别划分的全球遗传性慢性阻塞性肺疾病 (COPD) 市场：2017-2030

支气管扩张剂
4 型磷酸二酯□抑製剂
类固醇
抗生素
其他

第 6 章。按给药途径划分的全球遗传性慢性阻塞性肺疾病 (COPD) 市场：2017-2030

口语
鼻音

第 7 章。全球遗传性慢性阻塞性肺疾病 (COPD) 市场，按分销渠道，2017-2030

医院药房
零售药房
在线药店

第 8 章全球遗传性慢性阻塞性肺疾病 (COPD) 市场按地区划分，2017-2030

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
英国
德国
意大利
法国
西班牙
俄罗斯
其他欧洲
亚太地区
中国
印度
日本
东盟
澳大利亚
韩国
其他亚太地区
中东
海湾合作委员会
以色列
其他中东地区
非洲
北非
中非
南非

第9章竞争格局

热图分析
公司简介
- GSK Plc
- AstraZeneca Plc
- Merck（Sigma-Aldrich）
- Dey Pharma
- Grifols, S.A.
- Teva Pharmaceutical Industries Ltd
- Baxter
- Boehringer Ingelheim International GmbH
- Kamada Ltd
- Takeda Pharmaceutical Company Limited
- LFB SA
- Abeona Therapeutics
- Alnylam Pharmaceuticals, Inc.
- Vertex Pharmaceuticals Incorporated
- Kedrion S.p.A.
- Arrowhead Pharmaceuticals, Inc

第 10 章

参考文献
调查方法

简介目录

Product Code: CMI5512

Alpha-1 deficiency-related emphysema is called as genetic Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic illness, and some of its symptoms include wheezing, mucus production, and breathing difficulties. Chronic bronchitis, emphysema, and refractory asthma are all symptoms of COPD, a degenerative lung condition. Chronic obstructive pulmonary disease (COPD) is mostly brought on by smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (a rare form of COPD), and other factors.

Each year, millions of people are affected by chronic obstructive pulmonary disease, or COPD for short. Emphysema and chronic bronchitis are two conditions that are collectively referred to as COPD. The lungs' alveoli, which are air sacs, suffer damage in emphysema. Breathlessness while exercising is the first sign of emphysema. Later, breathing difficulties can also happen while at rest. The four stages of chronic obstructive pulmonary disease (COPD) range from mild to very severe. Some symptoms may include an ongoing cough, shortness of breath, and wheezing.

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product launch and approval is expected to drive market growth over the forecast period. For instance, in September 2020, GSK, Plc.,a pharmaceutical company and Innoviva Inc., a healthcare focused asset management company, announced that the U.S. Food and Drug Administration (FDA) approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the treatment of asthma in patients 18 years and older, expanding the current approval for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for the relief of acute bronchospasm. Moreover, several prospective drugs, primarily for COPD, are in the pipeline for respiratory illnesses, which is anticipated to boost growth of the global genetic chornic obstructive pulmonary disease (COPD) market.

Key features of the study:

This report provides an in-depth analysis of the global genetic chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (us$ million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
it profiles key players in the global genetic chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study GSK Plc., AstraZeneca Plc., Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global genetic chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genetic chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:
- Bronchodilators
- Phosphodiesterase Type 4 Inhibitors
- Steroids
- Antibiotics
- Others
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:
- Oral
- Nasal
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- GSK Plc*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AstraZeneca Plc
- Merck (Sigma-Aldrich)
- Dey Pharma
- Grifols, S.A.
- Teva Pharmaceutical Industries Ltd
- Baxter
- Boehringer Ingelheim International GmbH
- Kamada Ltd
- Takeda Pharmaceutical Company Limited.
- LFB SA
- Abeona Therapeutics
- Alnylam Pharmaceuticals, Inc.
- Vertex Pharmaceuticals Incorporated
- Kedrion S.p.A.
- Arrowhead Pharmaceuticals, Inc

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Key Highlights
Research and Development Collaboration, Mergers, and Acquisitions
PEST Analysis
Pipeline Analysis
Epidemiology

4. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market - Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Bronchodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Phosphodiesterase Type 4 Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Steroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Route Of Administration, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Nasal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa